What is INTEGRA Biosciences?
Founded in 1965 and headquartered in Grisons, Switzerland, with a critical operational hub in Hudson, New Hampshire, INTEGRA Biosciences is a premier provider of sophisticated laboratory instrumentation. The company specializes in advanced liquid handling solutions and media preparation systems, serving as a cornerstone for research and diagnostic laboratories worldwide. By maintaining a focus on ergonomic design and high-throughput efficiency, INTEGRA has established itself as a critical partner for biotech and pharmaceutical entities seeking to optimize their laboratory workflows and ensure experimental reproducibility.
How much funding has INTEGRA Biosciences raised?
INTEGRA Biosciences has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in INTEGRA Biosciences
PPP
Public-Private Partnership
What's next for INTEGRA Biosciences?
Looking ahead, the infusion of capital is expected to accelerate the development of next-generation automated liquid handling platforms. As the life sciences industry shifts toward higher levels of laboratory automation and digital integration, INTEGRA is well-positioned to leverage its deep domain expertise to capture additional market share. The strategic allocation of these funds will likely prioritize R&D initiatives aimed at enhancing precision, reducing manual intervention in complex assays, and expanding the company's reach into emerging high-growth markets. This trajectory suggests a sustained period of innovation and operational scaling, reinforcing the company's status as a leader in laboratory technology.
See full INTEGRA Biosciences company page
